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Background: 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) is
a well-established imaging modality for a wide variety of solid malignancies. Currently, only limited data exists regarding
the utility of PET/CT imaging at very extended injection-to-scan acquisition times. The current retrospective data analysis
assessed the feasibility and quantification of diagnostic 18F-FDG PET/CT oncologic imaging at extended injection-to-scan
acquisition time intervals.
Methods: 18F-FDG-avid lesions (not surgically manipulated or altered during 18F-FDG-directed surgery, and visualized
both on preoperative and postoperative 18F-FDG PET/CT imaging) and corresponding background tissues were assessed
for 18F-FDG accumulation on same-day preoperative and postoperative 18F-FDG PET/CT imaging. Multiple patient
variables and 18F-FDG-avid lesion variables were examined.
Results: For the 32 18F-FDG-avid lesions making up the final 18F-FDG-avid lesion data set (from among 7 patients), the
mean injection-to-scan times of the preoperative and postoperative 18F-FDG PET/CT scans were 73 (±3, 70-78) and 530
(±79, 413-739) minutes, respectively (P < 0.001). The preoperative and postoperative mean 18F-FDG-avid lesion SUVmax
values were 7.7 (±4.0, 3.6-19.5) and 11.3 (±6.0, 4.1-29.2), respectively (P < 0.001). The preoperative and postoperative
mean background SUVmax values were 2.3 (±0.6, 1.0-3.2) and 2.1 (±0.6, 1.0-3.3), respectively (P = 0.017). The preoperative
and postoperative mean lesion-to-background SUVmax ratios were 3.7 (±2.3, 1.5-9.8) and 5.8 (±3.6, 1.6-16.2), respectively,
(P < 0.001).
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Conclusions: 18F-FDG PET/CT oncologic imaging can be successfully performed at extended injection-to-scan acquisition
time intervals of up to approximately 5 half-lives for 18F-FDG while maintaining good/adequate diagnostic image quality.
The resultant increase in the 18F-FDG-avid lesion SUVmax values, decreased background SUVmax values, and increased
lesion-to-background SUVmax ratios seen from preoperative to postoperative
18F-FDG PET/CT imaging have great potential
for allowing for the integrated, real-time use of 18F-FDG PET/CT imaging in conjunction with 18F-FDG-directed
interventional radiology biopsy and ablation procedures and 18F-FDG-directed surgical procedures, as well as
have far-reaching impact on potentially re-shaping future thinking regarding the “most optimal” injection-to-
scan acquisition time interval for all routine diagnostic 18F-FDG PET/CT oncologic imaging.
Keywords: 18F-FDG, PET/CT, SUVmax, Injection-to-scan acquisition time, Delayed imaging, Lesion-to-background
ratio, Tumor-to-background ratio, 18F-FDG-directed surgery, Real-time, OncologicBackground
18F-fluorodeoxyglucose (18F-FDG) positron emission
tomography/computed tomography (PET/CT) is a
well-established imaging modality for a wide variety of
solid malignancies [1-5]. Its utilities have included
initial cancer diagnostics, staging, restaging, therapy
planning, therapy response monitoring, surveillance,
and cancer screening for at-risk populations. Beyond
these utilities, there has been growing interest in evalu-
ating the feasibility of utilizing 18F-FDG and PET/CT
technology for providing real-time information within
the operative room and perioperative arena [6-62].
As part of an effort to provide surgeons with improved
intraoperative tumor localization and image-based verifi-
cation of completeness of resection, our collaborative
group at The Ohio State University has previously de-
scribed a novel, multimodal imaging and detection strat-
egy involving perioperative patient and ex vivo surgical
specimen 18F-FDG PET/CT imaging performed in com-
bination with intraoperative 18F-FDG gamma detection
[51]. As part of this schema, patients could undergo
both a same-day preoperative diagnostic whole-body
18F-FDG PET/CT and a same-day postoperative diagnos-
tic limited field-of-view 18F-FDG PET/CT, utilizing a
single preoperative dose of 18F-FDG. This has provided
our group with a unique dual-set of diagnostic 18F-FDG
PET/CT images, in which the initial same-day preopera-
tive diagnostic whole-body 18F-FDG PET/CT images
were acquired within the injection-to-scan acquisition
time interval generally recommended for diagnostic
whole-body 18F-FDG PET/CT imaging [63], and in
which the second set of same-day diagnostic limited
field-of-view 18F-FDG PET/CT images were acquired
after the completion of the surgical procedure, once the
patient had completed standard postoperative recovery
in the post-anesthesia care unit. This second set of
same-day diagnostic limited field-of-view 18F-FDG PET/
CT images was highly dependent upon the length of the
surgical procedures performed, thus creating injection-
to-scan acquisition time intervals for that second set ofsame-day diagnostic limited field-of-view 18F-FDG PET/
CT images at time points far beyond what is generally
described.
The current retrospective data analysis was under-
taken to examine 18F-FDG-avid lesions and correspond-
ing background tissues on same-day preoperative and
postoperative 18F-FDG PET/CT scans to assess the feasi-
bility and quantification of diagnostic 18F-FDG PET/CT
oncologic imaging at extended injection-to-scan acquisi-
tion time intervals. Herein, we have: (1) demonstrated
the ability to acquire diagnostic quality images at ex-
tended injection-to-scan acquisition times; (2) identified
and quantified the amount of 18F-FDG accumulation in
18F-FDG-avid lesions and in corresponding background
tissues at these extended injection-to-scan acquisition
times; and (3) compared the amount of 18F-FDG accu-
mulation in 18F-FDG-avid lesions and in corresponding
background tissues at these extended injection-to-scan
acquisition times to that of the corresponding injection-
to-scan acquisition time interval generally recommended
for diagnostic whole-body 18F-FDG PET/CT oncologic
imaging.Methods
All aspects of the current retrospective analysis were ap-
proved by the Cancer Institutional Review Board (IRB)
at The Ohio State University Wexner Medical Center.
The data for the current retrospective analysis were ac-
quired from a master prospectively-maintained database
(with database inclusion dates from June 2005 to June
2012), which were generated from the combination of
several Cancer IRB-approved protocols, and which in-
volved a multimodal imaging and detection approach to
18F-FDG-directed surgery for the localization and resec-
tion of 18F-FDG-avid lesions in patients with known and
suspected malignancies. Depending upon the clinical
scenario, these 18F-FDG-directed surgical procedures
were performed with either the intent for curative resec-
tion, for palliation, or for making a definitive tissue
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ment for any given disease presentation.
All patients who were eligible to be included in this
current retrospective analysis consisted of those individ-
uals who: (1) received a same-day single-dose preopera-
tive intravenous injection of 18F-FDG; (2) underwent
same-day preoperative diagnostic whole-body 18F-FDG
PET/CT scan (usually consisting of 6 to 8 field-of-view
PET bed positions, and with 2 minutes of PET imaging
for each field-of-view PET bed position); (3) proceeded
to the operating room for their anticipated surgical pro-
cedure and completed standard postoperative recovery
in the post-anesthesia care unit; and (4) underwent a
same-day postoperative diagnostic limited field-of-view
18F-FDG PET/CT scan (which was limited only to the
immediate area of the surgical resection field, usually
consisting of 1 to 3 field-of-view PET bed positions, in
order to limit overall patient radiation exposure for the
CT portion of the PET/CT, and with 10 minutes of PET
imaging for each field-of-view PET bed position). All pa-
tients fasted for a minimum of 6 hours before undergo-
ing the same-day preoperative diagnostic whole-body
18F-FDG PET/CT scan. Only a single intravenous dose
of 18F-FDG was used on the day of surgery, and was
attempted to be administered approximately 75 minutes
prior to the planned time of the same-day preoperative
diagnostic whole-body 18F-FDG PET/CT scan, which
was performed within the time frame recognized by the
Society of Nuclear Medicine for 18F-FDG PET/CT image
acquisition [63]. The 18F-FDG PET/CT images were ac-
quired on one of three clinical diagnostic scanners: (1)
Siemens Biograph 16 (Siemens, Knoxville, Tennessee); (2)
Phillips Gemini TF (Philips, Amsterdam, Netherlands);
and (3) Siemens Biograph mCT (Siemens, Knoxville,
Tennessee). Only those patients with 18F-FDG-avid
lesions seen on both same-day preoperative diagnostic
whole-body 18F-FDG PET/CT scan and same-day postoper-
ative diagnostic limited field-of-view 18F-FDG PET/CT scan
were used in the current retrospective analysis. For any
individual patient, the same-day preoperative diagnostic
whole-body 18F-FDG PET/CT scan and same-day postoper-
ative diagnostic limited field-of-view 18F-FDG PET/CT scan
were performed on the same clinical diagnostic scanner.
The same-day preoperative diagnostic whole-body
18F-FDG PET/CT images and same-day postoperative
diagnostic limited field-of-view 18F-FDG PET/CT images
were evaluated by two nuclear medicine physicians who
were initially blinded to all clinical information related
to each set of preoperative and postoperative 18F-FDG
PET/CT images. The two nuclear medicine physician
readers first judged the quality of the preoperative and
postoperative 18F-FDG PET/CT images as either being
of diagnostic image quality or of non-diagnostic image
quality, based upon criteria that were previously reported[64]. The two readers evaluated each set of preoperative
and postoperative 18F-FDG PET/CT images for identifica-
tion of all 18F-FDG-avid lesions that were considered suspi-
cious for or consistent with malignancy. The location and
maximum standard uptake value (SUVmax) of each
18F-
FDG-avid lesion were recorded. Likewise, a corresponding
background SUVmax was obtained either from (1) an area
of tissue deemed as normal within the same organ as the
18F-FDG-avid lesion; (2) an area of tissue deemed as normal
in a location adjacent to the 18F-FDG-avid lesion; or (3)
within a single area of tissue deemed as normal elsewhere
within the body when multiple 18F-FDG-avid lesions were
being evaluated in an individual case. The corresponding
background SUVmax values were taken from the same
location on both the preoperative and postoperative
18F-FDG PET/CT scans. Finally, the two readers were
given access to the operative report for each case
corresponding to each preoperative and postoperative
18F-FDG PET/CT images data set, in order to deter-
mine which 18F-FDG-avid lesions had been: (1) completely
surgically resected; (2) partially surgically resected or
biopsied; or (3) not surgically manipulated or altered
(i.e., intentionally left in situ within the patient at
the time of the 18F-FDG-directed surgical procedure).
The 18F-FDG PET/CT images were all analyzed/processed
on a Philips Extended Brilliance Work Station (Philips,
Amsterdam, Netherlands).
All continuous variables were expressed as mean
(±SD, range). The software program IBM SPSS® 21 for
Windows® (SPSS, Inc., Chicago, Illinois) was used for the
data analysis. All mean value comparisons for continu-
ous variables (including the comparisons for 18F-FDG-
avid lesion SUVmax values, background SUVmax values,
and lesion-to-background SUVmax ratios) from the pre-
operative 18F-FDG PET/CT image group and the postoper-
ative 18F-FDG PET/CT image group were performed by
using the 2-tailed paired samples t-test. All categorical vari-
able comparisons were made using 2 × 2 contingency tables
that were analyzed by either the Pearson chi-square test or
the Fisher exact test, when appropriate. P-values deter-
mined to be 0.05 or less were considered to be statistically
significant.Results
Derivation of the final 18F-FDG-avid lesion data set
From a total of 166 patients who gave consent to partici-
pate in one of the IRB-approved protocols, a total of 157
patients were taken to the operating room for 18F-FDG-di-
rected surgery. A total of 31 of the 157 patients underwent
both a same-day preoperative diagnostic whole-body 18F-
FDG PET/CT scan and a same-day postoperative diagnos-
tic 18F-FDG PET/CT scan utilizing a single same-day
preoperative intravenous injection of 18F-FDG.
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FDG PET/CT images were evaluated by two nuclear
medicine physicians for determination of diagnostic
image quality versus non-diagnostic image quality. All of
the 31 preoperative 18F-FDG PET/CT imaging studies
were determined to be of diagnostic image quality. A
total of 5 of the 31 postoperative 18F-FDG PET/CT im-
aging studies were determined to be of non-diagnostic
image quality. The average injection-to-scan time for
these 5 postoperative 18F-FDG PET/CT studies with
non-diagnostic image quality was of significantly longer
duration, at 719 minutes (±90, 612-853), as compared to
530 minutes (±79, 413-739) for the remaining 26 postoper-
ative 18F-FDG PET/CT studies with diagnostic image qual-
ity (P < 0.001), suggesting that the finding of non-diagnostic
image quality on a postoperative 18F-FDG PET/CT scan
was a direct consequence of any given postoperative
18F-FDG PET/CT scan being performed at the extreme
outer-limit of the extended injection-to-scan acquisi-
tion time interval. No other 18F-FDG PET/CT imaging
variables or any patient variables were significantly
different for the postoperative non-diagnostic image
quality group as compared to the postoperative diag-
nostic image quality group.
From the 26 remaining matching sets of preoperative
and postoperative 18F-FDG PET/CT studies that were
determined to be of diagnostic image quality, a total of
87 individual 18F-FDG-avid lesions were identified on
the preoperative 18F-FDG PET/CT images. There were
30 18F-FDG-avid lesions identified on the preoperative
18F-FDG PET/CT images that were completely surgical
resected, 10 18F-FDG-avid lesions that were partially sur-
gically resected or biopsied, and 12 18F-FDG-avid lesions
were not within the field of view that was utilized on the
postoperative 18F-FDG PET/CT images (as the postoper-
ative 18F-FDG PET/CT scan was performed in a limited
fashion to only to the bed of the surgical resection field).
Therefore, these 52 of the original 87 individual 18F-FDG-
avid lesions identified on the preoperative 18F-FDG PET/
CT images were not considered for further data analysis.
The remaining 35 18F-FDG-avid lesions identified on
the preoperative 18F-FDG PET/CT images were deter-
mined to represent preoperative 18F-FDG-avid lesions
that had not been surgically manipulated and were left
in situ within the patient at the time of the surgical pro-
cedure, and were within the field of view on the postop-
erative 18F-FDG PET/CT images. There were 3 of these
remaining 35 preoperative 18F-FDG-avid lesions that
were not 18F-FDG-avid on the postoperative 18F-FDG
PET/CT images. Of the 3 preoperative 18F-FDG-avid le-
sions not found to be 18F-FDG-avid on the postoperative
18F-FDG PET/CT images, 2 preoperative 18F-FDG-avid
lesions were located within the bilateral tonsils in a pa-
tient who was later confirmed to have recurrent thyroidcancer within the mediastinum, but without any evi-
dence of metastatic spread to the tonsils. These 2 areas
of preoperative mild focal 18F-FDG-avidity seen within
the bilateral palatine tonsils (SUVmax 4.3 on the left and
4.0 on the right), but not found to be 18F-FDG-avid on
the postoperative PET/CT images, were determined to be
secondary to nonmalignant inflammation, a well-known
pitfall of diagnostic 18F-FDG PET/CT imaging of the tonsil-
lar region. The third preoperative 18F-FDG-avid lesion was
located within the stomach region of a patient with diffuse
metastatic serous ovarian cancer. This area of preoperative
focal 18F-FDG-avidity seen within the stomach region
(SUVmax 10.0), but not found to be
18F-FDG-avid on
the postoperative 18F-FDG PET/CT images, has not
been further evaluated to date secondary to the lack of
performance of any subsequent follow-up diagnostic
18F-FDG PET/CT imaging. As such, these 3 18F-FDG-avid
lesions were not considered for further data analysis. In the
end, a total of 32 of the original 87 individual 18F-FDG-avid
lesions identified on the preoperative 18F-FDG PET/CT im-
ages were considered as the final 18F-FDG-avid lesion data
set for the current retrospective data analysis comparing
the preoperative and postoperative 18F-FDG PET/CT
images. The region of the body in which these 32
18F-FDG-avid lesions were located was designated as
the thorax for 12 lesions, abdomen/pelvis for 11 le-
sions, neck for 5 lesions, and axilla for 4 lesions.
Patient variables
The 32 18F-FDG-avid lesions, constituting the final
18F-FDG-avid lesion data set, originated from a total 7
patients (5 females and 2 males) from among the initial
group of 31 patients who had undergone both a same-
day preoperative diagnostic whole-body 18F-FDG PET/CT
scan and a same-day postoperative diagnostic 18F-FDG
PET/CT scan. For those 7 patients, the mean patient age
was 65 (±12, 43-80) years, the mean patient weight was
80.3 (±28.1, 56.7-136.1) kilograms, the mean preoperative
blood glucose level of 103 (±15, 82-121) milligrams/deci-
liter, and the mean intravenous 18F-FDG dose used on the
day of surgery was 559 (±104, 437-755) megabecquerels. A
histologic diagnosis of malignancy was known to be lymph-
oma in 3 cases, colorectal carcinoma in 2, breast carcinoma
in 1, and ovarian carcinoma in 1.
Preoperative and postoperative 18F-FDG PET/CT scan
variables for the 32 18F-FDG-avid lesions and
corresponding background areas
For the 32 18F-FDG-avid lesions, the mean injection-to-
scan times of the preoperative and postoperative 18F-FDG
PET/CT scans were 73 (±3, 70-78) minutes and 530 (±79,
413-739) minutes, respectively (P < 0.001). The preoperative
and postoperative mean 18F-FDG-avid lesion SUVmax
values were 7.7 (±4.0, 3.6-19.5) and 11.3 (±6.0, 4.1-
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postoperative mean background SUVmax values were
2.3 (±0.6, 1.0-3.2) and 2.1 (±0.6, 1.0-3.3), respectively
(P = 0.017). The preoperative and postoperative mean
lesion-to-background SUVmax ratios were 3.7 (±2.3,
1.5-9.8) and 5.8 (±3.6, 1.6-16.2), respectively, (P <
0.001) (Table 1).
Two representative example cases of an 18F-FDG-avid
lesion seen on both same-day preoperative diagnostic
whole-body 18F-FDG PET/CT scan and same-day post-
operative diagnostic limited field-of-view 18F-FDG PET/
CT scan are shown in Figures 1 and 2.
Of the 32 18F-FDG-avid lesions examined, only 1
18F-FDG-avid lesion demonstrated a reduction in the
lesion-to-background SUVmax ratio from the preopera-
tive to the postoperative 18F-FDG PET/CT images.
This particular 18F-FDG-avid lesion was located in the
ascending colon of a patient with colorectal carcinoma,
having a preoperative 18F-FDG-avid lesion SUVmax of
7.9 (with a preoperative background SUVmax of 1.0)
and a postoperative 18F-FDG-avid lesion SUVmax of 7.5
(with a postoperative background SUVmax of 1.2),
resulting in a change in the lesion-to-background
SUVmax ratio of -1.7 from the preoperative to the post-
operative study. Interestingly, on a subsequent follow-
up diagnostic whole-body 18F-FDG PET/CT scan per-
formed 9 months after 18F-FDG-directed surgery, the same
area of this particular former 18F-FDG-avid lesion in the
ascending colon was no longer characterized as 18F-
FDG-avid, demonstrating a SUVmax of 2.1 (with a
background SUVmax of 1.7).
For the 32 18F-FDG-avid lesions, the corresponding
background SUVmax values were taken from contralateral
axillary region (n = 13), normal mediastinum (n = 10),
contralateral supraclavicular region (n = 4), normal adjacent
liver parenchyma (n = 2), hepatic flexure (n = 1), descending
colon (n = 1), and adjacent normal spleen (n = 1).
Discussion
The results of the current retrospective data analysis, com-
paring preoperative and postoperative 18F-FDG PET/CT
imaging for 32 individual 18F-FDG-avid lesions (not surgi-
cally manipulated or altered during 18F-FDG-directed
surgery, and for which all such 18F-FDG-avid lesions wereTable 1 Preoperative and postoperative 18FDG PET/CT scan vari
background areas
Variable Preoperative scan v
Injection-to-scan time (minutes) 73 (±3, 70-78)
18F-FDG-avid lesion SUVmax 7.7 (±4.0, 3.6-19.5)
Background SUVmax 2.3 (±0.6, 1.0-3.2)
Lesion-to-background SUVmax ratio 3.7 (±2.3, 1.5-9.8)
All variables are expressed as mean (±SD, range).
Abbreviations: 18F-FDG 18F-fluorodeoxyglucose, PET/CT positron emission tomographvisualized on both preoperative and postoperative 18F-FDG
PET/CT imaging), yielded several very important observa-
tions. First, 18F-FDG PET/CT imaging performed at ex-
tended injection-to-scan acquisition times of up to a mean
time of 530 minutes (i.e., approximately 5 half-lives for 18F-
FDG) was able to maintain a designation of good/adequate
diagnostic image quality deemed necessary for clinical
interpretation. Second, the mean 18F-FDG-avid lesion
SUVmax value increased significantly from preoperative to
postoperative 18F-FDG PET/CT imaging (7.7 to 11.3; P <
0.001). Third, mean background SUVmax value decreased
significantly from preoperative to postoperative 18F-FDG
PET/CT imaging (2.3 to 2.1; P = 0.017). Fourth, the mean
lesion-to-background SUVmax ratio increased significantly
from preoperative to postoperative 18F-FDG PET/CT im-
aging (3.7 to 5.8; P < 0.001). These collective observations
from our current analysis have potential far-reaching impli-
cations regarding the currently held premises related to
18F-FDG PET/CT oncologic imaging.
Multiple investigators [65-169] have evaluated the
concepts of delayed phase and dual-time-point diagnos-
tic 18F-FDG PET imaging approaches. In these numer-
ous studies, attempts have been made to qualify and
quantify the impact of the length of the injection-to-
scan time interval on differentiating malignant processes
from benign processes. As one might expect, the find-
ings reported amongst these various investigators have
been highly variable, with some supporting the use of
delayed phase and dual-time-point diagnostic 18F-FDG
PET imaging approaches [66-77,81-84,86,87,91-93,95-
100,103-108,110,111,113,114,117-122,124-128,131,133,134,
136,138,141,143,146,149,152,153,155,157,160-163,165,167,
169], and with others not [65,78,89,90,94,101,102,109,115,
116,123,129,130,132,135,137,139,140,147,148,150,151,156,
158,164,166,168].
The inherent difference in intracellular glucose-6-
phosphatase levels, as it relates to benign cells and
tumor cells, can be used to support the notion that
the delayed phase and dual-time-point diagnostic 18F-
FDG PET/CT imaging approaches are advantageous
[36,100,111,154,159,170-176]. Initially, benign cells,
such as in the case of inflammatory processes, may
appear hypermetabolic as they transport increased
number of glucose molecules into their cytoplasm.ables for the 32 18F-FDG-avid lesions and corresponding
alue Postoperative scan value P-value
530 (±79, 413-739) <0.001
11.3 (±6.0, 4.1-29.2) <0.001
2.1 (±0.6, 1.0-3.3) 0.017
5.8 (±3.6, 1.6-16.2) <0.001
y/computed tomography, SUVmax maximum standard uptake value.
Figure 1 A representative example of an 18F-FDG-avid lesion in the left supraclavicular region (shown within the yellow circle) as seen
on both same-day preoperative diagnostic whole-body 18F-FDG PET/CT scan (panel A; SUVmax of 16.7 at 70 minutes post-injection of
455 megabecquerels of 18F-FDG) and same-day postoperative diagnostic limited field-of-view 18F-FDG PET/CT scan (panel B; SUVmax of
20.5 at 494 minutes post-injection of 18F-FDG) in a patient with metastatic ovarian carcinoma.
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to the fact that those benign cells contain normal levels of
intracellular glucose-6-phosphatase, thus allowing glucose
molecules to subsequently exit the cytoplasm of those cells
via glucose transporter membrane proteins. On the other
hand, tumor cells have decreased levels of intracellular
glucose-6-phosphatase, thus allowing for a continuous
accumulation of 18F-FDG into tumor cell over time.
Therefore, methodologies that use a delayed phase in
their diagnostic 18F-FDG PET imaging approach should
allow for an expected gradual decline in intracellular
18F-FDG retention within initially hypermetabolic-
appearing benign tissues as compared to the continued
accumulation of intracellular 18F-FDG within malig-
nant tissues [100,111,154,159].
Nevertheless, there are several reasons why the notion
that delayed phase and dual-time-point diagnostic 18F-FDG
PET imaging approaches are advantageous may not be so
simple and clear cut. First, it is well-recognized that there
can be a significant degree of overlap in the pattern
of 18F-FDG uptake between benign tissues and
various malignant tissues [154,159]. Second, there aresubstantial inherent variations in the methodology
used in various delayed phase and dual-time-point
diagnostic 18F-FDG PET imaging protocols from insti-
tution to institution, with great variability in the timing
of the initial scan and the delayed scan, as well as a
general paucity of data where the delayed scan is per-
formed at very extended injection-to-scan acquisition
time intervals after the initial time of 18F-FDG injec-
tion. Collectively, the vast majority of the reported
series within the literature performed their delayed
scan within approximately 1.5 to 2.5 hours from the
initial time of 18F-FDG injection [65,67,70-74,79,82,
83,85-93,97-100,102-104,106,107,109,110,112,113,115-
127,129-135,137-143,145-169], and with far fewer series
reporting their delayed scan at injection-to-scan acquisition
times of approximately 3 hours or more from the initial
time of 18F-FDG injection [66,68,69,75-78,80,81,84,94-96,
101,105,108,111,114,128,136,144].
There are 5 groups of investigators, Lodge et al. in
1999 [68], Spence et al. in 2004 [81], Basu et al. in 2009
[111], Horky et al. in 2011 [136], and Prieto et al. in
2011 [144], who all performed delayed phase diagnostic
Figure 2 A representative example of an 18F-FDG-avid lesion
in the right hepatic lobe of the liver (shown within the yellow
circle) as seen on both same-day preoperative diagnostic
whole-body 18F-FDG PET/CT scan (panel A; SUVmax of 8.2 at 73
minutes post-injection of 585 megabecquerels of 18F-FDG)
and same-day postoperative diagnostic limited field-of-view
18F-FDG PET/CT scan (panel B; SUVmax of 9.8 at 688 minutes
post-injection of 18F-FDG) in a patient with metastatic
colorectal carcinoma.
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acquisition time intervals, for which their clinical findings
are particularly noteworthy of further discussion.
As pertaining specifically to 18F-FDG PET imaging for
brain tumors, there have been 3 clinical series that have
reported successful delayed imaging extending out to
ultra-extended injection-to-scan acquisition time inter-
vals [81,136,144]. Spence et al. reported dual-time-point
diagnostic 18F-FDG PET imaging in various brain tu-
mors with a median time of 5.4 hours (range of 2.9 to
9.4 hours) after 18F-FDG injection for the delayed scan
in a series of 25 patients [81]. Prieto et al. reported dual-
time-point diagnostic 18F-FDG PET/CT imaging in gli-
omas with a range of 180 to 480 minutes after 18F-FDG
injection for the delayed scan in a series of 19 patients
[144]. In both series [81,144], they reported better tumor
identification and delineation, and advocated the use ofdelayed intervals imaging. Horky et al. reported dual-
time-point diagnostic 18F-FDG PET imaging in patients
treated with radiation for brain metastases, with delayed
scans performed at a mean time of 225 minutes (range
of 118 to 343 minutes) after the early scan done at 45 to
60 minutes after 18F-FDG injection in a series of 32 pa-
tients [136]. They found that although the early and late
SUVmax values of the lesions alone did not differentiate
residual tumor from post-radiation necrosis, the change
in the lesion-to-gray matter early SUVmax ratio to late
SUVmax ratio did.
Along similar lines for 18F-FDG PET imaging of soft
tissues masses, Lodge et al. reported a series of 29 pa-
tients in which a 6-hour 18F-FDG PET imaging protocol
was used [68]. In this protocol, a 2-hour dynamic emis-
sion data acquisition was performed after 18F-FDG ad-
ministration, followed by 2 further 30-minute static
scans, which were started at 4 hours and 6 hours after
18F-FDG administration. They found that the SUV value
for high-grade sarcomas increased with time, reaching a
peak SUV value at approximately 4 hours after initial
18F-FDG administration, while benign soft tissue lesions
reached a maximum SUV value within approximately
30 minutes after initial 18F-FDG administration. They
concluded that improved differentiation of high-grade
sarcomas from benign soft tissue lesions was aided by
SUV values derived from delayed intervals imaging.
Likewise, for 18F-FDG PET imaging of non-small cell
lung cancer, Basu et al. reported on 3 patients in whom
an 8-hour 18F-FDG PET imaging protocol was used
[111]. In this protocol, 18F-FDG PET imaging was per-
formed, starting at 5 minutes, and continuing at 1, 2, 4,
6, and 8 hours after initial 18F-FDG administration. They
found that sites of non-small cell lung cancer showed a
progressive increase in 18F-FDG uptake over the 8-hour
course, while surrounding normal tissues demonstrated
either a declining or stable pattern of 18F-FDG uptake
with time. They concluded that delayed injection-to-
scan acquisition time intervals had “implications in de-
tecting malignant lesions with greater degree of certain-
ty”…“due to better contrast between the abnormal site
and the surrounding background”.
Of last mention, similar recommendations for the use
of delayed injection-to-scan acquisition time interval im-
aging have been made by other investigators at somewhat
less extended injection-to-scan acquisition time intervals
of approximately 3 hours in breast cancer [66,105,128],
cervical cancer [76,77], hepatocellular cancer [84], biliary
malignancies [95], lung cancer [75,96,108], and thymic epi-
thelial tumors [114].
The results of the previously reported series demonstrat-
ing their ability to successfully perform delayed imaging at
extended injection-to-scan acquisition time intervals of
approximately 3 hours or more from the initial time of 18F-
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111,114,128,136,144], as well as those demonstrating the
added value to performing delayed imaging at extended
injection-to-scan acquisition time intervals of approxi-
mately 3 hours or more from the initial time of
18F-FDG injection [66,68,75-77,81,84,95,96,105,108,111,
114,128,136,144], are all highly consistent with the re-
sults of our current retrospective data analysis. It is clear
that our currently presented data, demonstrating in-
creasing 18F-FDG-avid lesion SUVmax values, decreasing
background SUVmax values, and increasing lesion-to-
background SUVmax ratios from preoperative to postopera-
tive 18F-FDG PET/CT imaging, supports the potential
utility of delayed phase and dual-time-point diagnostic 18F-
FDG PET/CT imaging. This suggests that delayed scans
performed at an appropriately selected extended injection-
to-scan acquisition times can potentially minimize or allevi-
ate the issue of overlap in the pattern of 18F-FDG uptake
between benign tissues versus malignant tissues, as well as
between background tissues versus malignant tissues. This
phenomenon appears to be the temporal outcome of a re-
sultant gradual accumulation of 18F-FDG within malignant
tissues and continued decreased background level of 18F-
FDG within the surrounding normal tissues, thus leading
to a progressive increase in the lesion-to-background
SUVmax ratio. A key element to this overall line of reason-
ing, as it relates to the proper use of 18F-FDG in molecular
imaging, is the recognition of the negative impact of “back-
ground” issues, and “not signal”, as recently eloquently de-
scribed by Frangioni [177], but which was recognized early
on in the evolution of PET imaging by Hoffman and Phelps
[178]. This time-dependent phenomenon observed in our
current retrospective analysis is consistent with our previ-
ously reported findings regarding same-day preoperative
diagnostic whole-body 18F-FDG PET/CT images and same-
day perioperative ex vivo surgical specimen 18F-FDG PET/
CT imaging, in which we observed similar trends of in-
creased 18F-FDG accumulation in 18F-FDG-avid lesions
within ex-vivo surgical specimens and of decreased
18F-FDG activity within adjacent normal tissues [37].
However, we fully acknowledge and recognize that sig-
nificant further investigations are warranted to better
assess this phenomenon and to formally evaluate the
clinical usefulness of extended injection-to-scan acqui-
sition time intervals in various diagnostic 18F-FDG
PET/CT oncologic imaging applications.
Analogous to our current discussions regarding the
evaluation and quantification of 18F-FDG-avid lesions
and corresponding background tissues at these ex-
tended injection-to-scan acquisition time intervals for
18F-FDG PET imaging approaches, there have been two
groups of investigators utilizing 18F-FDG-directed surgery
[11,17,21], other than our own collaborative group [51],
who have previously examined the equivalent question as itpertains to the impact of the length of time from injection
of 18F-FDG to the performance of intraoperative gamma
detection probing [11,17,21]. One such group [17,21] rec-
ognized that there was an increased tumor-to-background
ratio of 18F-FDG seen during intraoperative gamma detec-
tion probing when there was a longer duration (i.e., up to 6
hours of time) from injection of the 18F-FDG dose to intra-
operative probing. However, they did not endorse lengthen-
ing the duration from injection of the 18F-FDG dose to
performing intraoperative gamma detection probing or to
performing perioperative 18F-FDG PET imaging [21]. In-
stead, they specifically commented that lengthening the
duration from injection of the 18F-FDG dose “might
compromise image quality as a result of lower count
rates” [21]. The other such group [11], as based upon
the evaluation of 18F-FDG count rates for only three
patients, concluded that intraoperative gamma detec-
tion probing was “more suitable” at 1 to 3 hours
post-injection of 18F-FDG as compared to 6 to 7 hours
post-injection of 18F-FDG. In both instances, these two
groups of investigators fell short of recognizing the
potential efficacies of extended injection-to-scan acquisition
time intervals.
Although we clearly recognize that the current retro-
spective data analysis is based upon only 32 individual
18F-FDG-avid lesions, the potential significance of our
current collective observations is far-reaching for 18F-
FDG PET/CT oncologic imaging. While the possibility
of ultra-extended injection-to-scan acquisition time in-
tervals of up to approximately 5 half-lives for 18F-FDG
was first alluded to in the dose uptake ratio simulation
studies by Hamberg et al. in 1994 [179] and was later
clinically examined by Lodge et al. in 1999 [68], Spence
et al. in 2004 [81], Basu et al. in 2009 [111], Horky et al.
[136], and Prieto et al. in 2011 [144], its potential future
impact has not previously been fully realized within the
nuclear medicine or surgical literature. The ability to
maintain good/adequate diagnostic image quality for
18F-FDG PET/CT imaging at extended injection-to-scan
acquisition time intervals of up to approximately 5 half-
lives and the resultant time-dependent increase in the
observed 18F-FDG-avid lesion SUVmax values, decrease
in the observed background SUVmax values, and increase
in the lesion-to-background SUVmax ratios allow for and
justify the more widespread and integrated, real-time use
of diagnostic 18F-FDG PET/CT imaging in conjunction
with 18F-FDG-directed interventional radiology biopsy
procedures and ablation procedures, as well as with
18F-FDG-directed surgical procedures. Such integrated,
real-time utilities for diagnostic 18F-FDG PET/CT imaging
would facilitate periprocedural verification of appropriate
tissue targeting during 18F-FDG-directed interventional
radiology biopsy procedures and ablation procedures and
for perioperative verification of appropriate tissue targeting
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surgical procedures. Furthermore, these resultant time-
dependent observations could have far-reaching impact on
potentially re-shaping future thinking regarding what repre-
sents the “most optimal” injection-to-scan acquisition time
interval for all routine diagnostic 18F-FDG PET/CT onco-
logic imaging, as the current procedure guideline for tumor
imaging with 18F-FDG PET/CT, as published by the Society
of Nuclear Medicine, simply states that “emission images
should be obtained at least 45 minutes after radiopharma-
ceutical injection” [63].
Conclusions
Our current retrospective data analysis demonstrates
that 18F-FDG PET/CT oncologic imaging can be suc-
cessfully performed at extended injection-to-scan acqui-
sition time intervals of up to approximately 5 half-lives
for 18F-FDG while maintaining good/adequate diagnostic
image quality. The resultant increased 18F-FDG-avid
lesion SUVmax values, decreased background SUVmax
values, and increased lesion-to-background SUVmax ra-
tios seen from preoperative to postoperative 18F-FDG
PET/CT imaging have great potential for allowing for
the integrated, real-time use of 18F-FDG PET/CT im-
aging in conjunction with 18F-FDG-directed interventional
radiology biopsy and ablation procedures and 18F-FDG-di-
rected surgical procedures, as well as have far-reaching im-
pact on potentially re-shaping future thinking regarding the
“most optimal” injection-to-scan acquisition time interval
for all routine diagnostic 18F-FDG PET/CT oncologic im-
aging. In these regards, we fully acknowledge and recognize
the need for further investigations to better assess and
formally evaluate the clinical utility of extended injection-
to-scan acquisition time intervals in various diagnostic 18F-
FDG PET/CT oncologic imaging applications.
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